Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab Compared With Chemotherapy in Patients With Treatment Naïve Advanced or Recurrent (Stage IIIb Not Amenable for Multimodality Treatment) or Metastatic (Stage IV) Non-Small Cell Lung Cancer Who Are Deemed Unsuitable for Platinum-Containing Therapy
Brief Summary: This Phase III, global, multicenter, open-label, randomized, controlled study will evaluate the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 \[anti-PD-L1\] antibody) compared with a single agent chemotherapy regimen by investigator choice (vinorelbine or gemcitabine) in treatment-naïve participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are deemed unsuitable for any platinum-doublet chemotherapy due to poor performance status (Eastern Cooperative Oncology Group \[ECOG\] performance status of 2-3).


Options:
A: Arm Label: Atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody | Arm Label: Single Agent Chemotherapy (Vinorelbine or Gemcitabine); Type: ACTIVE_COMPARATOR; Interventions: Drug: Vinorelbine, Drug: Gemcitabine | Intervention Type: DRUG; Name: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody; Assigned to Arm(s): Atezolizumab | Intervention Type: DRUG; Name: Vinorelbine; Assigned to Arm(s): Single Agent Chemotherapy (Vinorelbine or Gemcitabine) | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Single Agent Chemotherapy (Vinorelbine or Gemcitabine)
B: Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): N/A
C: Arm Label: Pembrolizumab + Chemotherapy Combo; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab, Drug: Paclitaxel, Drug: Nab-paclitaxel, Drug: Carboplatin | Arm Label: Placebo + Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Nab-paclitaxel, Drug: Carboplatin, Drug: Saline placebo for pembrolizumab | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Nab-paclitaxel; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Pembrolizumab + Chemotherapy Combo, Placebo + Chemotherapy | Intervention Type: DRUG; Name: Saline placebo for pembrolizumab; Assigned to Arm(s): Placebo + Chemotherapy
D: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm B: Docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: Docetaxel

Answer: A